Nonclinical Assessment of the Effect of Taprenepag Isopropyl (PF-04217329) Formulated With and Without Benzylkonium Chloride (BAC) and Xalatan® on Intraocular Exposure of the Active Metabolites of Taprenepag (CP-544326) and Xalatan® (Latanoprost Acid)